<DOC>
	<DOCNO>NCT01936883</DOCNO>
	<brief_summary>Optimal non surgical treatment prostate cancer require dose escalation frequently provide add brachytherapy `` boost '' short course external beam radiotherapy . The hypothesis randomize study High Dose Rate ( HDR ) brachytherapy boost lead equivalent good Prostate Specific Antigen ( PSA ) recurrence-free survival compare Low Dose Rate ( LDR ) brachytherapy boost associate favorable toxicity profile improve quality life .</brief_summary>
	<brief_title>Improving Quality Life After Prostate Brachytherapy : Comparison HDR LDR Brachytherapy</brief_title>
	<detailed_description>Men intermediate high risk prostate cancer technically suitable prostate brachytherapy base prostate size void function interested modality treatment approach randomization either high dose rate ( single 15 Gray ) low dose rate permanent seed implant ( 110 Gray ) brachytherapy . Baseline International Prostate Symptom score , Quality Life Assessment International Index Erectile Function record every 3 month first year every 6 month 3 year . Androgen deprivation treatment allow 6 12 month .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Upper tier intermediate risk least 2 follow factor 1 . TumorNodesMetastases Tumor stage T2B great 2 . Gleason Score 7 3 . PSA &gt; 10 4 . &gt; 50 % biopsy positive OR High risk prostate cancer one follow factor 1 . T3a 2 . Gleason Score810 3 . PSA &gt; 20 Positive prostate biopsy within 6 month ( review centrally ) International Prostate Symptom Score &lt; 16 Prostate volume &lt; 60 cc Negative stag CT Bone scan within 3 month prior registration History physical examination within 90 day prior registration European Cooperative Oncology Group performance status 01 prior registration Age &gt; 45 Patient suitable procedure anesthesia Prior invasive malignancy ( except non melanoma skin cancer ) unless diseasefree least 3 year prior registration Previous prostatectomy , cryotherapy High Intensity Focussed Ultrasound prostate cancer Previous pelvic irradiation prostate brachytherapy</criteria>
	<gender>Male</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>prostatic neoplasm</keyword>
	<keyword>brachytherapy</keyword>
	<keyword>quality life</keyword>
	<keyword>high dose rate</keyword>
	<keyword>low dose rate</keyword>
</DOC>